United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease
INCREASE Study is First to Demonstrate a Clear Benefit in Patients with PH-ILD, a Life-threatening Disease with No Currently FDA-Approved Treatments
Company to host a webcast detailing the INCREASE study results on Tuesday, January 19, 2021 at 4:30 p.m. E.T.
News provided by
Share this article
Share this article
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 13, 2021 /PRNewswire/ United Therapeutics Corporation (Nasdaq: UTHR) today announced that results from the
INCREASE clinical study of Tyvaso
® (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) have been published online in the
Gender difference in mortality among pulmonary tuberculosis HIV co-infected adults aged 15-49 years in Kenya
Rose J. Kosgei , Roles Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Resources, Software, Supervision, Validation, Writing – original draft, Writing – review & editing
Affiliation Ghent University, Faculty of Medicine and Health Sciences, Ghent, Belgium ⨯
Peter Gichangi,
Affiliation Department of Human Anatomy, University of Nairobi, Nairobi, Kenya ⨯
Marleen Temmerman, Roles Conceptualization, Methodology, Supervision, Writing – review & editing
Affiliations Ghent University, Faculty of Medicine and Health Sciences, Ghent, Belgium, Aga Khan University, Faculty of Health Sciences, Nairobi, Kenya ⨯
Anne-Beatrice Kihara,
Affiliation Department of Obstetrics and Gynaecology, University of Nairo